BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.17 Consensus Target Price from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $15.17.

Several equities research analysts have weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays lifted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Needham & Company LLC increased their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, Evercore ISI lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $7.64 on Thursday. The firm has a market cap of $1.58 billion, a P/E ratio of -12.52 and a beta of 1.76. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The stock’s 50-day moving average is $7.57 and its two-hundred day moving average is $7.66.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same period in the previous year, the business posted ($0.19) earnings per share. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently made changes to their positions in BCRX. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares during the last quarter. DRW Securities LLC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter worth $74,000. KBC Group NV lifted its position in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares in the last quarter. Finally, Xponance Inc. lifted its holdings in BioCryst Pharmaceuticals by 13.1% during the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,505 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.